Atypical Neuroleptic Malignant Syndrome With Quetiapine

El-Gaaly, Sherief; John, P. S.; Dunsmore, Sara; Bolton, James M.

doi:10.1097/jcp.0b013e3181b4b091

Cited by 21 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, recent studies found no significant difference between typical and atypical APDs in the emergence of TD (Miller et al 2008;Correll and Schenk 2008). Similarly, there is increasing evidence that treatment with atypical APDs may also result in NMS (El-Gaaly et al 2009;Morris et al 2009;Trollor et al 2009). …”

Section: Toxicity Studiesmentioning

confidence: 94%

Regional Differences in the Action of Antipsychotic Drugs: Implications for Cognitive Effects in Schizophrenic Patients

et al. 2010

View full text Add to dashboard Cite

Antipsychotic drugs (APDs) have been classified as typical or atypical based on their liability to produce extrapyramidal side effects: atypical APDs are less likely to produce extrapyamidal side effects at therapeutic doses. Evidence from immediate early gene immunohistochemical, electrophysiological, microdialysis, imaging, and behavioral studies suggests that typical APDs preferentially affect the nucleus accumbens (NAc) and the dorsal striatum while atypical APDs preferentially affect the NAc and medial prefrontal cortex (PFC). We review some of this evidence and then discuss studies that have employed cognitive tasks shown previously to depend on dorsal striatal or medial PFC function in schizophrenic patients treated with typical or atypical APDs. Results revealed that patients treated with typical APDs displayed deficits in cognitive tasks that depended on the dorsal striatum but not in tasks that depended on the medial PFC and that those treated with atypical APDs displayed deficits in cognitive tasks that depended on the medial PFC but not in cognitive tasks that depended on the dorsal striatum. These findings suggest that some of the cognitive deficits seen in schizophrenic patients may be related to the medications that are used to treat them.

show abstract

Section: Toxicity Studiesmentioning

confidence: 94%

Regional Differences in the Action of Antipsychotic Drugs: Implications for Cognitive Effects in Schizophrenic Patients

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Although NMS usually occurs during the use of typical antipsychotic drugs, cases have been reported with the use of atypical antipsychotic drugs (6,9). In the literature, 12 cases have been noted in which NMS developed during the use of quetiapine.…”

Section: Discussionmentioning

confidence: 99%

Neuroleptic Malignant Syndrome During the use of Extended Release Quetiapine: A Case Report

Akyüz

Oflaz

Üstün

et al. 2012

Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychophar

View full text Add to dashboard Cite

“…Mortality and morbidity associated with NMS can be further reduced by increased awareness of its initial clinical symptoms and signs, allowing for prompt clinical menagement 33 . Newer agents, typically regarded as safe, are also not uncommonly related to NMS and the use of these AP should not preclude diagnostic suspicion 4,11,[14][15][16][17] .…”

Section: Discussionmentioning

confidence: 99%

“…NMS is classically associated with the use of high-potency antipsychotics (AP), such as butyrophenones and phenothiazines, but has also been described with newer agents, commonly described as "atypical" AP (risperidone, olanzapine, quetiapine), other D2-receptor antagonists (metoclopramide) and following withdrawal of anti dopaminergic agents [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19] . Although the precise pathophysiologic mechanism underlying NMS remains unknown, a reduction in dopaminergic activity in the brain probably by dopamine D2 receptor blockade in the striatum and hypothal-amus is generally assumed as a potential cause 4,20 .…”

mentioning

confidence: 99%

Neuroleptic malignant syndrome

Moscovich

Novak

Fernandes

et al. 2011

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

Neuroleptic malignant syndrome (NMS) is a potentially fatal adverse event associated with the use of antipsychotics (AP). The objective of this study was to investigate the profile of cases of NMS and to compare our findings with those published in similar settings. A series of 18 consecutive patients with an established diagnosis of NMS was analyzed, gathering data on demography, symptoms and signs. Two thirds of all cases involved woman with a past medical history of psychiatric disorder receiving relatively high doses of AP. The signs and symptoms of NMS episodes were similar to those reported in other series and only one case had a fatal outcome, the remaining presenting complete recovery. As expected, more than two thirds of our cases were using classic AP (68%), however the clinical profile of these in comparison with those taking newer agent was similar. Newer AP also carry the potential for NMS. Key words: atypical antipsychotics, typical antipsychotics, neuroleptic malignant syndrome.Síndrome neuroléptica maligna RESUMO A síndrome neuroléptica maligna (SNM) é um evento adverso potencialmente fatal associado ao uso de antipsicóticos (AP). O objetivo deste estudo foi investigar as características clínicas de cases da SNM e comparar nossos resultados com os publicados na literatura. Uma série de 18 pacientes com diagnóstico confirmado de SNM foram analisados, associando dados demográficos, apresentação clínica, diagnóstico e tratamento. Dois terços dos casos envolveram mulheres com antecedentes psiquiátricos que recebeceram doses relativamente altas de AP. Os sinais e sintomas foram semelhantes àqueles já relatados na literatura e a maioria dos pacientes teve uma recuperação completa, exceto por um caso com desfecho fatal. Houve predomínio de pacientes que usam medicamentos neurolépticos clássicos (68%), porém não houve diferença nas manifestações destes casos em relação àqueles que usavam AP novos. AP mais novos também têm o potencial de causar SNM. Palavras-Chave: neurolépticos atípicos, neurolépticos típicos, síndrome neuroléptica maligna.

show abstract

Atypical Neuroleptic Malignant Syndrome With Quetiapine

Cited by 21 publications

References 17 publications

Regional Differences in the Action of Antipsychotic Drugs: Implications for Cognitive Effects in Schizophrenic Patients

Regional Differences in the Action of Antipsychotic Drugs: Implications for Cognitive Effects in Schizophrenic Patients

Neuroleptic Malignant Syndrome During the use of Extended Release Quetiapine: A Case Report

Neuroleptic malignant syndrome

Contact Info

Product

Resources

About